Buller C - Search Results

1

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.

Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH; REGULATE-PCI Investigators. Lincoff AM, et al. Among authors: buller c. Lancet. 2016 Jan 23;387(10016):349-356. doi: 10.1016/S0140-6736(15)00515-2. Epub 2015 Nov 5. Lancet. 2016. PMID: 26547100 Clinical Trial.

2

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.

O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, Gilchrist IC, Kleiman NS, Labinaz M, Madan M, Hafley GE, Califf RM, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators. O'Shea JC, et al. Among authors: buller ce. JAMA. 2002 Feb 6;287(5):618-21. doi: 10.1001/jama.287.5.618. JAMA. 2002. PMID: 11829701 Clinical Trial.

3

Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.

Tcheng JE, Madan M, O'Shea JC, Cohen EA, Buller CE, Lincoff AM, Popma JJ, Teirstein PS, Kitt MM, Lorenz TJ, Greenberg S, Fost N, Califf RM. Tcheng JE, et al. J Interv Cardiol. 2003 Apr;16(2):97-105. doi: 10.1046/j.1540-8183.2003.08020.x. J Interv Cardiol. 2003. PMID: 12768912

4

The 2004 ACC/AHA Guidelines: a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group.

Armstrong PW, Bogaty P, Buller CE, Dorian P, O'Neill BJ; Canadian Cardiovascular Society Working Group. Armstrong PW, et al. Can J Cardiol. 2004 Sep;20(11):1075-9. Can J Cardiol. 2004. PMID: 15457302

5

Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction.

Dorian P, Bogaty P, Buller CE, O'Neill BJ, Armstrong PW; Canadian Cardiovascular Society Working Group. Dorian P, et al. CMAJ. 2004 Oct 26;171(9):1042-4. doi: 10.1503/cmaj.1041418. CMAJ. 2004. PMID: 15505263 Free PMC article. No abstract available.

6

A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.

Madan M, Labinaz M, Cohen EA, Buller CE, Cantor WJ, Seidelin P, Ducas J, Carere RG, Natarajan MK, Pieper KS, Hafley GE, O'Shea JC, Kitt MM, Califf RM, Tcheng JE; ESPRIT Investigators. Madan M, et al. Can J Cardiol. 2004 Nov;20(13):1343-9. Can J Cardiol. 2004. PMID: 15570357 Clinical Trial.

7

Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.

Buller CE, Pate GE, Armstrong PW, O'Neill BJ, Webb JG, Gallo R, Welsh RC. Buller CE, et al. Can J Cardiol. 2006 May 1;22(6):511-5. doi: 10.1016/s0828-282x(06)70271-9. Can J Cardiol. 2006. PMID: 16685318 Free PMC article.

8

Coronary intervention for persistent occlusion after myocardial infarction.

Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL; Occluded Artery Trial Investigators. Hochman JS, et al. Among authors: buller ce. N Engl J Med. 2006 Dec 7;355(23):2395-407. doi: 10.1056/NEJMoa066139. Epub 2006 Nov 14. N Engl J Med. 2006. PMID: 17105759 Free PMC article. Clinical Trial.

9

A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.

Welsh RC, Gordon P, Westerhout CM, Buller CE, O'Neill B, Armstrong PW. Welsh RC, et al. Among authors: buller ce. Catheter Cardiovasc Interv. 2007 Sep;70(3):341-8. doi: 10.1002/ccd.21062. Catheter Cardiovasc Interv. 2007. PMID: 17295333 Clinical Trial.

10

Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.

Dzavík V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS; SHould we inhibit nitric Oxide synthase in Cardiogenic shocK 2 (SHOCK-2) investigators. Dzavík V, et al. Eur Heart J. 2007 May;28(9):1109-16. doi: 10.1093/eurheartj/ehm075. Epub 2007 Apr 25. Eur Heart J. 2007. PMID: 17459901 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters